EUCTR2007-007045-12-IT进行中（未招募）不适用
An open label, single institution, phase II study of the mTOR inhibitor temsirolimus in unresectable and/or metastatic renal cell carcinoma (RCC) in patients previously treated with both cytokines and one ore more tyrosine kinase inhibitor, The TeRCC study - ND
OSPEDALE POLICLINICO S. MATTEO0 个研究点开始时间: 2008年1月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •age >/= 18 years, cyto-hystological diagnosis of renal cell carcinoma, previous treatment with both cytokines and one or more kinase inhibitors, measurable disease, ...
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Major surgical procedure within 28 days prior to study treatment start, other malignancies within the last 5 years, clinically significant cardiovascular disease, myocardial infarction, unstable angina, history of other disease, metabolic disfunction, concomitant radiotherapy in the site of disease, previous radiotherapy or other locoregional antitumoral treatment performed within 21 days before the study recruitment, uncontrolled hyperglicemia, ...
研究者
相似试验
进行中（未招募）
2 期
An open label, single centre, phase II pilot study of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanomaCancer - Malignant melanomaMelanomaACTRN12613000737730Melanoma Institute Australia35
招募中
1 期
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patientsCTIS2023-505241-10-00Medibiofarma S.L.10
已完成
1 期
Phase I / IIa trial of R-OKY-034F for pancreatic cancer patientsC535836Pancreatic cancerJPRN-jRCT2051190003Takehara Tetsuo30
招募中
1 期
Phase I / IIa trial of R-OKY-034F long-term administration for pancreatic cancer patientsPancreatic cancerJPRN-jRCT2051200105Kusaka Haruki30
进行中（未招募）
不适用
A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome - MEPOCHUSSChurg-Strauss-SyndromeMedDRA version: 9.1Level: LLTClassification code 10009164Term: Churg Strauss syndromeEUCTR2006-001791-20-DEniversity Hospital of Schleswig-Holstein (UKSH), Campus Lübeck